




Searching News Database: hepatic encephalopathy
HSMN NewsFeed - 29 Feb 2016
Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA
Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA
HSMN NewsFeed - 30 Mar 2015
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
HSMN NewsFeed - 24 May 2013
PBAC Approves XIFAXAN(R) (Rifaxamin α) 550 mg Cost Effectiveness in Australia
PBAC Approves XIFAXAN(R) (Rifaxamin α) 550 mg Cost Effectiveness in Australia
HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
HSMN NewsFeed - 12 May 2008
Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
HSMN NewsFeed - 4 Oct 2007
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
HSMN NewsFeed - 7 Sep 2007
Arbios Systems Publishes Positive Results From Completed Sepet(TM) Feasibility Clinical Trial
Arbios Systems Publishes Positive Results From Completed Sepet(TM) Feasibility Clinical Trial
HSMN NewsFeed - 27 Oct 2006
Arbios Systems Announces Presentation of SEPET(TM) Clinical Data at the 57th Annual AASLD Meeting
Arbios Systems Announces Presentation of SEPET(TM) Clinical Data at the 57th Annual AASLD Meeting
Additional items found! 3

Members Archive contains
3 additional stories matching:
hepatic encephalopathy
(Password required)
hepatic encephalopathy
(Password required)